Reversible ON- and OFF-switch chimeric antigen receptors controlled by lenalidomideMax Jan, Benjamin L. Ebert, Andrea Schmidts et al.|Science Translational Medicine|2021Cited by 257
Targeting solid tumor antigens with chimeric receptors: cancer biology meets synthetic immunologyGabriele Kembuan, Max Jan|Trends in cancer|2024Cited by 27
Chemical genetic control of cytokine signaling in CAR-T cells using lenalidomide-controlled membrane-bound degradable IL-7Michael C. Kann, Max Jan|Leukemia|2023Cited by 6
Exploiting the Zinc Finger Degrome Targeted By Lenalidomide to Engineer Reversible Off-Switch Degradable Chimeric Antigen ReceptorsMax Jan, Benjamin L. Ebert, Ana P. Castaño et al.|Blood|2019Cited by 0